Skip to content
Buy This GLP
← Research
Evidence

Does Medicare Cover Ozempic and Wegovy? Part D and the GLP-1 Bridge

Part D coverage depends on the indication. Since July 2026, a separate Medicare GLP-1 Bridge offers eligible patients access with a $50 copay.

Editorial profile: Carla MedinaBuy This GLP Editorial Team6 min read
Medicare fee-for-service, Part Dhad a covered indication35.1%…of those, had a claim16.5%full cohort with a claim6.2%Outlined bar is the whole group being described.

Medicare can cover these drugs for eligible indications, subject to plan rules. For weight management, the separate Medicare GLP-1 Bridge began July 1, 2026, with a $50 copay for eligible beneficiaries. It operates outside ordinary Part D coverage and currently runs through December 31, 2027.[4]CMS lists Wegovy injections and tablets for eligible weight-management prescriptions through the Bridge. Ozempic is outside the Bridge’s eligible product list.[5]

In the historical study below, roughly 1.2 million had obesity alone and did not meet the study’s covered-indication definition. Those figures do not measure access through the newer Bridge. KFF’s 2026 survey found that 18% of firms with at least 200 workers that offered benefits covered GLP-1s for weight loss in their largest plan[2]. The employer coverage guide explains how to check your own plan.

Ask your prescriber which pathway applies to your actual diagnosis and prescription. The Bridge copay does not count toward Part D true out-of-pocket spending. Compare Medicare payment routes before paying cash.[4]

Coverage on paper is also not the same as a filled prescription. In a survey from one academic medical center, 159 of 261 respondents (60.9%) reported a prior-authorization requirement. Of those respondents, 29 received approval after more than seven days. Another 50 were still waiting or had never been approved. Together, they represented 49.7% of the 159 respondents[3]. Our guide to GLP-1 prior-authorization timelines explains what those responses can tell you about delays.

A retrospective study of 2023–2024 Medicare claims measured GLP-1 use among adults continuously enrolled in fee-for-service Parts A, B and D throughout both years[1]. The national analysis of who the price filtered out examines access in a broader population.

Across Medicare fee-for-service beneficiaries with Part D coverage (n = 16,474,786), 6.2% had a claim for one of these drugs. A much larger group, 35.1%, already carried a condition Medicare covers them for. Type 2 diabetes, established cardiovascular disease with overweight or obesity, obstructive sleep apnea with obesity, or metabolic dysfunction-associated steatohepatitis.

About 1.2 million beneficiaries, or 7%, had obesity without another condition that met the study’s definition of a covered indication. That reflects the ordinary Part D weight-loss exclusion, rather than eligibility under the later Bridge demonstration. For other covered indications, the diagnosis and plan criteria still determine access. It is also why the study counts potential future indications at all: 76.9% had at least one current or possible future qualifying condition.

The authors then model what would change if Medicare covered heart failure with preserved ejection fraction, chronic kidney disease, psoriasis or knee osteoarthritis. About 35% of the group with obesity and no covered indication, about 407,085 people, could gain access under those assumptions. The estimate measures potential eligibility. The study did not estimate how many people would fill a prescription under expanded coverage[1].

If your plan denies coverage, use the GLP-1 insurance coverage guide to check whether the decision can be appealed. If you are comparing self-pay options, the monthly cost guide explains how to compare medication, membership and other fees on the same basis.

Frequently asked

Does Medicare cover GLP-1 drugs for weight loss?
Ordinary Part D still excludes drugs used only for weight loss, but the separate Medicare GLP-1 Bridge began in July 2026. Eligible beneficiaries can access selected drugs with a $50 copay outside Part D; other indications use the usual coverage pathway.
If I qualify, will I get it?
Your prescriber and plan can confirm the requirements for your prescription. In the 2023–2024 fee-for-service study, 16.5% of people with a covered condition had a GLP-1 claim. The study did not measure an individual patient’s chance of approval.
Who was included in the claims study?
The study included adults continuously enrolled in Medicare fee-for-service Parts A, B and D during 2023 and 2024. Medicare Advantage enrollees were outside the study cohort.

Sources

  1. [1] Kim S, Barthel A, Smurzynski M, MacEwan J (2026). Prevalence of Obesity and Related Conditions and GLP-1 Use in Medicare Fee-for-Service Beneficiaries Diabetes, Obesity & Metabolism. PMID 42348175
  2. [2] KFF (2026). 2026 Employer Health Benefits Survey KFF. Source
  3. [3] Chen Y, et al. (2026). Patient-Reported Continuity of GLP-1 Receptor Agonist Therapy Obesity Science & Practice. PMID 42683049
  4. [4] Centers for Medicare & Medicaid Services (2026). Medicare GLP-1 Bridge CMS. Source
  5. [5] Centers for Medicare & Medicaid Services (2026). Medicare GLP-1 Bridge: eligible products and formulations CMS guidance for Part D plans. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence